Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer

Maurie Markman, MD

August 22, 2022

Liquid biopsy, also known as ctDNA, is emerging as a complementary technique to NGS. Liquid biopsy is being explored to screen for cancers, diagnose cancers, monitor for progression or relapse, and direct therapy selection. Studies have shown that liquid biopsy, with a broader view of systemic tumor evolution, can yield valuable information for certain tumor types that might be missed with localized tissue biopsy. Recent advances in NGS technology enable comprehensive genomic profiling combined with the sensitivity and specificity required for liquid biopsy applications.

Learn more about liquid biopsy with NGS technology.

Editor's Recommendations

Non–Small Cell Lung Cancer

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Maurie Markman. Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer - Medscape - Aug 22, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Maurie Markman, MD

Comments

Email This

Feedback